文献速递产科母胎医学

疑似子痫前期胎盘生长因子检测的成本效益分析

Placental growth factor testing for suspected pre-eclampsia: a cost-effectiveness analysis.
PubMed 文献 · BJOG · 2019-07-17

该成本效益分析基于PARROT阶梯楔形整群随机对照试验,纳入英国11个产科单位中孕20+0至36+6周疑似子痫前期的孕妇,采用蒙特卡洛模拟比较胎盘生长因子(PlGF)检测联合临床管理算法与现行标准护理的成本与母婴结局。结果显示PlGF检测策略成本更低且孕产妇不良结局更少,每例检测总节约149英镑,英格兰NHS每年潜在节约2,891,196英镑。

要点

  • PlGF检测联合临床管理算法较现行标准护理成本更低,每例检测总节约149英镑。
  • PlGF检测策略孕产妇不良结局更少,英格兰NHS每年潜在节约2,891,196英镑。
  • 该经济学分析支持在产科门诊对疑似子痫前期孕妇实施PlGF检测。

核心结论

  • 疑似子痫前期孕妇接受PlGF检测联合临床管理算法的临床护理,较现行实践每例检测有潜在成本节约,并通过减少门诊就诊改善孕产妇结局。
  • 该经济学分析支持在产科服务中实施PlGF检测以评估疑似子痫前期孕妇。

研究设计与样本

  • 成本效益分析,基于参与PARROT阶梯楔形整群随机对照试验的11个产科单位。
  • 研究对象为孕20+0至36+6周疑似子痫前期的孕妇。
  • 采用蒙特卡洛模拟,利用资源使用数据和孕产妇不良结局。

主要发现

  • PlGF检测的临床护理成本低于现行标准实践,且孕产妇不良结局更少。
  • 包含检测费用在内,每例受检者总成本节约149英镑。
  • 在英格兰NHS范围内,每年潜在成本节约为2,891,196英镑。

临床怎么用

  • 该经济学分析支持在产科门诊对疑似子痫前期孕妇实施PlGF检测。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To calculate the cost-effectiveness of implementing PlGF testing alongside a clinical management algorithm in maternity services in the UK, compared with current standard care. DESIGN: Cost-effectiveness analysis. SETTING: Eleven maternity units participating in the PARROT stepped-wedge cluster-randomised controlled trial. POPULATION: Women presenting with suspected pre-eclampsia between 20+0 and 36+6 weeks' gestation. METHODS: Monte Carlo simulation utilising resource use data and maternal adverse outcomes. MAIN OUTCOME MEASURES: Cost per maternal adverse outcome prevented. RESULTS: Clinical care with PlGF testing costs less than current standard practice and resulted in fewer maternal adverse outcomes. There is a total cost-saving of UK£149 per patient tested, when including the cost of the test. This represents a potential cost-saving of UK£2,891,196 each year across the NHS in England. CONCLUSIONS: Clinical care with PlGF testing is associated with the potential for cost-savings per participant tested when compared with current practice via a reduction in outpatient attendances, and improves maternal outcomes. This economic analysis supports a role for implementation of PlGF testing in antenatal services for the assessment of women with suspected pre-eclampsia. TWEETABLE ABSTRACT: Placental growth factor testing for suspected pre-eclampsia is cost-saving and improves maternal outcomes.

来源:BJOG,查看原文。版权归原作者所有。

引用

  1. Duhig KE, Seed PT, Myers JE, et al. Placental growth factor testing for suspected pre-eclampsia: a cost-effectiveness analysis. BJOG. 2019. PMID: 31240854. doi:10.1111/1471-0528.15855

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。